Did a pricey cholesterol-lowering drug really reduce deaths, as headlines claim?
NEJM reignites conflict-of-interest debate with reader poll
It’s good to see others get in on the media watchdog work
Monday health news roundup: mostly gems, one dud
After Barcelona buzz wears off, questions remain about new heart drugs
What the public doesn’t see about pharma trying to buy influence